Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$85.37M+416.68%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dominick C. Colangelo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 398
- Beta
- 1.06
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 13.62
Financials
Revenue
$85.37M+416.7%Net Income
$14.16MEBITDA
$17.95MFree Cash Flow
$15.68MEPS (diluted)
$0.27Shares Outstanding (diluted)
52.96M+117.7%Operating Expenses
$50.42MCash & Debt
$170.27MReturn of Capital
$8.55MRevenue by Segment (annual)
$239.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $276.26M | $16.52M | $0.33 |
| 2024 | $237.22M | $10.36M | $0.21 |
| 2023 | $197.52M | $-3.18M | $-0.07 |
| 2022 | $164.37M | $-16.71M | $-0.35 |
| 2021 | $156.18M | $-7.47M | $-0.16 |
| 2020 | $124.18M | $2.86M | $0.06 |
| 2019 | $117.85M | $-9.66M | $-0.18 |
| 2018 | $90.86M | $-8.14M | $-0.20 |
| 2017 | $63.92M | $-17.29M | $-0.52 |
| 2016 | $54.38M | $-19.57M | $-0.85 |
| 2015 | $51.17M | $-16.34M | $-0.69 |
| 2014 | $28.80M | $-19.92M | $-1.71 |
| 2013 | $19.0K | $-15.62M | $-5.18 |
| 2012 | $21.0K | $-29.47M | $-14.31 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.48
- Implied price
- $8.64
- Return from $57.48
- -31.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.29 — -92.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -42.7% | -40.1% | -37.9% | -35.9% | -34.2% |
| 3.0% | -39.8% | -37.1% | -34.7% | -32.7% | -30.9% |
| 8.0% | -36.9% | -34.0% | -31.6% | -29.4% | -27.5% |
| 13.0% | -34.0% | -30.9% | -28.4% | -26.1% | -24.1% |
| 18.0% | -31.0% | -27.9% | -25.2% | -22.9% | -20.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·9d ago·Neutral
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026 BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Stephens Annual Investment Conference at 4:30 p.m. ET (3:30 p.m. CT) on Wednesday, November 18, 2026.
View source ↗ - Newszacks.com·12d ago·Positive
Earnings Estimates Moving Higher for Vericel (VCEL): Time to Buy? Vericel Corporation (VCEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Vericel Q3 Earnings Call Highlights Vericel NASDAQ: VCEL raised its full-year revenue and profitability outlook after third-quarter sales rose 26%, led by growth in its MACI cartilage repair product and a record quarter for its burn care business.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Vericel Corporation (VCEL) Q3 2026 Earnings Call Transcript Vericel Corporation ( VCEL ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Richard Newitter - Truist Securities, Inc., Research Division R…
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026 BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Vericel: MACI And Regenerative Knee Cartilage Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.57 per share
Typical surprise +75.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.27 vs $0.06beat
- Thu, Jul 30$0.04 vs $-0.03beat
- Thu, May 7$-0.12 vs $-0.15beat
- Thu, Feb 26$0.45 vs $0.45beat
- Thu, Nov 6$0.10 vs $-0.02beat
- Thu, Jul 31$-0.01 vs $-0.04beat
Estimates and results for VCEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VCEL officers and directors.
- Bought
- —
- Sold
- $9.9m
0 trades
30 trades
- Mara Joseph Anthony Jrsold
- Mclaughlin Kevin Fsold
- Mara Joseph Anthony Jrsold
- Zerbe Robert L Mdsold
- Mara Joseph Anthony Jrsold
- Mara Joseph Anthony Jrsold
- Mara Joseph Anthony Jrsold
- Mara Joseph Anthony Jrsold
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VCEL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
